Orthofix Medical Inc. (NASDAQ: OFIX) said that Vitale Lucas, the companys Chief Product and Business Operations Officer, sold a total of 2,312 shares of common stock in two separate transactions conducted on March 4 and March 5, 2026. The sales were executed to cover tax liabilities associated with the settlement of restricted stock units.
On March 4, Lucas sold 1,171 shares at a weighted average price of $12.9163, with transaction prices in the range of $12.80 to $13.03. The following day, March 5, Lucas sold 1,141 shares at a weighted average price of $12.5508, with individual trade prices between $12.48 and $12.72. Combined, the transactions generated approximately $29,445 in proceeds.
After these dispositions, Lucas is reported to directly own 164,718 shares of Orthofix common stock, of which 138,173 are restricted stock units. The companys shares are trading at $12.62, a level that represents a 27% decline over the past year. Despite the year-over-year decline, an analysis by InvestingPro is cited as indicating that Orthofix is still undervalued at current market levels.
Separately, Orthofix announced results for the fourth quarter of fiscal 2025 that exceeded consensus expectations on key metrics. The company posted an earnings per share loss of $0.06, versus analyst forecasts that called for a $0.22 loss, marking a positive surprise of 72.73%. Revenue for the quarter was $219.9 million compared with consensus expectations of $218.57 million.
The better-than-expected EPS outcome and the slight revenue outperformance contributed to a favorable market reaction to the earnings release. For investors seeking more detailed valuation and performance metrics, a Pro Research Report covering Orthofix is available on InvestingPro, alongside reports on more than 1,400 other U.S. companies.
Clear summary
Vitale Lucas sold 2,312 shares on March 4-5, 2026 to cover RSU-related tax obligations, leaving him with 164,718 shares including 138,173 RSUs. The sales totaled about $29,445. Orthofix reported Q4 2025 results that beat EPS and revenue expectations, and the stock trades at $12.62, down 27% year over year while InvestingPro flags it as undervalued.
- Key points:
- Insider sale: 2,312 shares sold over two days to satisfy RSU tax obligations; proceeds approximated $29,445.
- Post-transaction ownership: Lucas holds 164,718 shares, including 138,173 restricted stock units.
- Earnings and market context: Q4 2025 EPS loss of $0.06 beat expectations of a $0.22 loss (72.73% positive surprise); revenue $219.9 million versus $218.57 million expected; share price at $12.62, down 27% over one year.
- Risks and uncertainties:
- Insider transactions to cover tax obligations may be routine and not indicative of a change in executive conviction; the sale was limited in size relative to total holdings.
- Share price has declined 27% over the past year, pointing to market volatility in the stock despite the recent quarters modest beat; market sentiment may continue to affect liquidity and valuation.
- While the company narrowly exceeded revenue and EPS expectations for Q4 2025, future quarters remain uncertain and may influence stock performance.
Tags: Healthcare, Orthopedics, Insider, Earnings, OFIX